Schwarzites are named after Hermann Schwarz, the 19th-century German mathematician who first described these intriguing periodic minimal surfaces characterized by intricate curvature and large surface area combined with remarkably low density. Despite their appealing mathematical elegance and theoretical allure, the physical synthesis of schwarzites has proven elusive. Unlike more familiar carbon nanostructures such as graphene and carbon nanotubes, schwarzites feature a complex arrangement of polygons that create a saddle-shaped, negatively curved surface. This inherent geometric complexity has posed a formidable challenge to chemists attempting to assemble such structures from sp²-hybridized carbon atoms.

Professor Würthner’s team has developed an innovative supramolecular approach to tackle this challenge, leveraging the unique properties of nanographene molecules incorporating heptagonal rings. Whereas standard graphene is composed purely of hexagonal carbon rings generating flat sheets, the introduction of heptagons induces curvature, creating the negative Gaussian curvature that is the hallmark of schwarzite structures. This method was recently demonstrated through assembling nanographene units around C60 fullerenes, achieving schwarzite-like arrangements exhibiting the targeted three-dimensional architecture.

A central element of this endeavor is the polymerization of these heptagon-containing nanographene building blocks into extended three-dimensional pi-conjugated frameworks. By advancing the synthetic sophistication of these components and fine-tuning their chemical environment, the research seeks to generate bulk schwarzite materials that embody the theorized electronic and mechanical properties. Such materials could offer exceptional electrical conductivity due to their fully delocalized electron systems spanning multiple dimensions, a feat unachieved by planar graphene or tubular nanotubes.

From a physical standpoint, schwarzites distinguish themselves through their unique topological electronic characteristics. Theorists predict that certain schwarzite lattices host Dirac cones—linear energy-momentum dispersions that are foundational to phenomena such as high electron mobility and exotic quantum phases of matter. If experimentally realized, these properties could unlock new physics and potential applications in quantum materials and electronic devices, positioning schwarzites as the next frontier for carbon-based nanotechnology.

The University of Würzburg’s Center for Nanosystems Chemistry, under Würthner’s leadership, is at the heart of this ambitious project. The center benefits from cutting-edge instrumentation and advanced facilities, courtesy of prior investments by the Free State of Bavaria. These resources will facilitate detailed characterization of newly synthesized schwarzites, ranging from structural analysis via electron microscopy to probing electronic behavior through spectroscopic methods. Understanding structure-property relationships in such novel materials is essential to harness their potential for practical applications.

This ERC-funded project represents Würthner’s second Advanced Grant, underscoring his position as a leading figure in organic and supramolecular chemistry. His earlier grant supported pioneering work in artificial photosynthesis, focusing on developing catalysts capable of splitting water molecules efficiently to produce clean hydrogen fuel. That success demonstrates his team’s capacity to address major scientific challenges by melding fundamental chemistry with visionary technological goals.

Würthner’s strategic approach integrates molecular design, supramolecular assembly, and polymer chemistry, pushing the boundary where synthetic chemistry meets materials science. By meticulously controlling the molecular architecture of nanographenes and their assembly into three-dimensional networks, the research aims to fabricate schwarzites with customizable properties. Such control over curvature and electronic conjugation could herald a new class of carbon materials tailored for specific applications in energy, filtration, and electronics.

The implications of successfully synthesizing schwarzites extend far beyond academic curiosity. Porous three-dimensional carbon frameworks with superior electrical conductivity and stability may revolutionize battery electrodes by enhancing charge transport and enabling faster ion diffusion. Similarly, their large internal surface area combined with tunable chemical functionality could make them ideal candidates for selective gas separation or water purification systems, addressing urgent environmental needs.

Yet, despite these exciting prospects, challenges remain immense. The synthetic routes to carefully incorporate heptagonal defects into extended carbon networks must be exquisitely precise to ensure desired curvature and connectivity. Additionally, ensuring the scalability and reproducibility of such complex materials will be crucial for transitioning from laboratory samples to practical technological components.

Professor Würthner’s vision exemplifies the synergy between mathematical theory and chemical innovation. By translating Schwarz’s 19th-century geometric abstractions into real, functional materials, this project blurs the boundary between abstract science and applicative technology. The successful realization of schwarzite materials would not only validate decades of theoretical predictions but also open transformative pathways in nanomaterial design and functional carbon architectures.

As the SCHWARZITE project unfolds over the coming five years, the scientific community will keenly watch Würthner’s progress. With robust ERC funding and a pioneering research team, the prospects for overcoming longstanding obstacles to schwarzite synthesis have never looked more promising. This work heralds a new era in carbon nanomaterials, potentially reshaping technologies across sectors from sustainable energy to environmental remediation.

In sum, Professor Frank Würthner’s ERC-funded pursuit of schwarzite carbon materials epitomizes cutting-edge research at the interface of chemistry, physics, and materials science. Harnessing molecular design and supramolecular chemistry, his project aspires to manifest exotic carbon allotropes long confined to mathematical theory into the tangible realm of high-performance nanomaterials. Their realization would mark a milestone in carbon materials science, paving the way for unprecedented technological innovations.

Subject of Research:
Synthesis and characterization of schwarzite carbon nanomaterials through supramolecular chemistry approaches for advanced energy and filtration applications.

Article Title:
Professor Frank Würthner’s Quest to Synthesize Schwarzite Carbon Nanostructures Powered by ERC Advanced Grant

News Publication Date:
Not provided

Web References:
https://mediasvc.eurekalert.org/Api/v1/Multimedia/43b03666-166c-477c-949e-8eb612c9e6af/Rendition/low-res/Content/Public

Image Credits:
Christoph Weiss / University of Würzburg

Keywords

Supramolecular chemistry, Nanostructures, Carbon allotropes

The ERC Advanced Grant is among the most competitive scientific funding instruments in Europe, awarded exclusively on the merit of scientific excellence and innovation. Researchers who push the boundaries of conventional knowledge and open novel avenues of investigation are eligible for this grant. Each award can provide up to 2.5 million euros over five years, allowing recipients to pursue transformative projects with significant societal and scientific impact. Professor Durante’s receipt of this grant signifies the high regard for his pioneering work and its potential to influence cancer therapy profoundly.

With an internationally acclaimed career spanning over three decades, Professor Durante is recognized as a world authority in radiation biology and medical physics. His remarkable contributions span charged particle therapy — a cancer treatment modality leveraging beams of charged ions — and the complex field of radioprotection in space. Durante’s research portfolio includes significant advancements in biodosimetry of charged particles, optimization of particle therapy techniques, and strategies to shield astronauts from cosmic radiation. His work has consistently driven improvements in treatment precision and effectiveness, with a strong translational focus on enhancing patient outcomes.

This new ERC-funded project, titled “Heavy Ion FLASH” or “HI-FLASH,” seeks to harness very heavy ions delivered in ultra-high intensity bursts to combat brain cancer. The current clinical landscape predominantly employs high-energy protons or carbon ions to treat various solid malignancies, including those in the brain. However, glioblastoma multiforme (GBM), a highly aggressive and treatment-resistant brain tumor, remains a formidable challenge with poor prognosis despite these therapies. HI-FLASH represents a bold effort to expand the therapeutic arsenal against such formidable cancers by exploring the potential of heavier ion species at unprecedented dose rates.

The underlying innovation of HI-FLASH centers on employing ions heavier than carbon, such as neon (^20Ne), to target hypoxic, fast-dividing, and highly resistant tumors like glioblastoma. While these heavier ions promise superior tumor control due to their heightened linear energy transfer (LET) properties, their clinical use is curtailed by significant toxicity to surrounding healthy tissues. Durante’s approach is to mitigate this limitation by exploiting the “FLASH effect”— a phenomenon whereby delivering radiation doses at ultra-high dose rates within sub-second timescales appears to spare normal tissues while preserving tumoricidal efficacy.

Although the precise molecular mechanisms underpinning the FLASH effect remain elusive, it represents a paradigm shift in radiotherapy. Early preclinical and clinical research has demonstrated that ultra-high dose rate irradiation can radically increase the therapeutic window, reducing side effects that typically limit dose intensification. Professor Durante’s group pioneered the first experimental demonstration of the FLASH effect utilizing high-energy carbon ions, a breakthrough that paved the way for considering even heavier ions. The HI-FLASH project aims to extend this paradigm to neon ions, hypothesizing that their increased mass and energy deposition characteristics may offer superior outcomes for tumors traditionally resistant to standard approaches.

A critical part of the research involves comparative studies investigating not only neon ions at conventional versus ultra-high dose rates but also high-energy protons under similar conditions. While protons generally exhibit limited efficacy against glioblastoma, they have shown a remarkable capacity to protect normal brain tissue under FLASH irradiation. By juxtaposing these different ion species and dose delivery regimes, Durante’s team hopes to elucidate novel treatment combinations that maximize tumor eradication while minimizing collateral damage to healthy tissue.

The unique facilities at the GSI Helmholtzzentrum für Schwerionenforschung campus in Darmstadt provide the ideal infrastructure for this pioneering investigation. The GSI synchrotron stands as the only worldwide accelerator capable of producing and accelerating ion species heavier than carbon at the energies and intensities necessary for FLASH radiotherapy studies. Moreover, the upcoming FAIR (Facility for Antiproton and Ion Research) accelerator center promises to significantly augment these capabilities, offering functionality that could propel HI-FLASH to new frontiers in particle therapy research and clinical translation.

Should HI-FLASH succeed in delineating protocols that safely and effectively employ heavy ions at ultra-high dose rates, it could revolutionize oncological treatment, especially for patients afflicted by highly resistant and lethal tumors. These advances may yield therapy regimens that circumvent the limitations of conventional radiotherapy, notably by widening the therapeutic window to allow higher doses without proportional increases in side effects. This research holds great promise not only for improving survival but also for enhancing quality of life among cancer patients facing dire prognoses.

Expressing his gratitude upon receiving this grant, Professor Durante emphasized the tremendous opportunity that the funding presents to accelerate transformative research in tumor therapy using charged particles. He anticipates fruitful collaboration with his team and experts from the GSI Biophysics and Accelerator departments over the next five years. This endeavor represents an extraordinary chance to transition sophisticated basic research insights into tangible medical innovations and clinical progress.

The recognition of Professor Durante’s work extends beyond the ERC award itself. He has garnered numerous distinguished honors spanning institutions and countries, reflecting his global standing in the field. Notably, he has received the Galileo Galilei Prize from the European Federation of Organizations for Medical Physics, the Warren Sinclair Award from the U.S. National Council on Radiation Protection, and prizes from the European Physical Society and Radiation Research Society. Furthermore, his leadership as president of the Particle Therapy Co-Operative Group (PTCOG), a prominent international consortium of particle therapy centers, underscores his role in steering the future trajectory of charged particle therapy worldwide.

The momentum built upon Durante’s prior ERC Advanced Grant-funded project “BARB” lays a solid foundation for HI-FLASH. The BARB initiative focused primarily on enhancing the precision of tumor therapy with heavy ions and recently submitted impactful findings describing improvements in treatment accuracy and outcomes. The technical insights and experimental experience garnered during BARB are directly informing the design and execution of HI-FLASH, enabling a seamless and highly informed continuation of this cutting-edge research trajectory.

In sum, Professor Marco Durante’s latest ERC-funded research stands poised to tackle one of the most pressing challenges in oncology — improving therapeutic options for glioblastoma and similarly aggressive tumors — by leveraging novel physics and radiobiological concepts rooted in ultra-high dose rate heavy-ion irradiation. The outcomes of HI-FLASH may redefine radiation oncology principles and open unprecedented clinical possibilities, illustrating the powerful intersection of fundamental science, advanced technology, and patient-centered innovation.

Subject of Research:
Advancement of ultra-high dose rate heavy ion radiotherapy for treatment-resistant brain tumors.

Article Title:
Pioneering Ultra-High Dose Rate Heavy Ion Therapy: Professor Marco Durante’s Quest to Revolutionize Tumor Treatment

News Publication Date:
2024

Web References:

• https://erc.europa.eu/news-events/news/erc-2024-advanced-grants-results
• https://www.gsi.de/en/work/research/biophysics

Image Credits:
© G. Otto, GSI/FAIR

Keywords

Health and medicine; Diseases and disorders; Cancer; Biophysics; Life sciences; Physical sciences; Physics; Accelerator physics

DIMERCIRCUITS embodies a radical technological ambition: to engineer DNA-based biological circuits that act dynamically and reversibly in response to cellular environments. Unlike traditional gene therapies that often rely on static expression systems, these circuits enable real-time, fine-tuned control of gene dosage. This breakthrough addresses a fundamental challenge in gene therapy—balancing the therapeutic efficacy against safety concerns such as off-target effects, unwanted immune responses, and gene dosage toxicity. The approach promises to deliver safer and more effective treatments by ensuring genes can be turned on or off as needed with surgical precision.

At the core of this innovation lies a modular platform that harnesses engineered transcription factors, termed MAD-TFs, and their tailored inhibitors, ΔTFs. These molecular tools function as biological counterparts to electronic transistors, which form the basis of traditional circuits. By assembling these ‘biological transistors’ into customizable configurations, researchers can design genetic circuits capable of complex, programmable behaviors directly encoded within living cells. This pioneering concept, enabled by computational design, creates a new language for gene regulation—one that can be tailored to the unique molecular signature of individual diseases or patients.

This engineered platform is not only versatile but also compact enough to be adapted for clinical use, overcoming several limitations faced by conventional therapeutics. For example, its ability to respond rapidly to intracellular cues allows for nuanced modulation of therapeutic genes, a feature critical for diseases where dosage sensitivity dictates clinical outcomes. By integrating feedback mechanisms and environmental responsiveness, these circuits embody a new generation of gene therapy tools designed for personalized medicine at the molecular level.

DIMERCIRCUITS takes a translational focus on Friedreich’s ataxia, a devastating rare neurodegenerative disorder caused by mutations in the FXN gene leading to mitochondrial dysfunction and progressive neurological decline. To rigorously test the efficacy and safety of these genetic circuits, di Bernardo’s team collaborates with Vania Broccoli, Group Leader at San Raffaele Hospital and Director of the Research Institute of Neuroscience (CNR) in Milan. Their joint effort employs brain organoids—miniaturized and simplified versions of the human brain grown in vitro from patient-derived cells—providing a unique and physiologically relevant platform to model human neurodegeneration with unprecedented fidelity.

By utilizing such patient-specific organoids, DIMERCIRCUITS transcends traditional preclinical models, offering profound insights into disease mechanisms and therapeutic responses at the tissue level. This strategy ensures that synthetic circuits do not merely function in artificial systems but demonstrate real-world efficacy and safety in human-like neural environments, representing a major advance toward clinical translation.

Professor di Bernardo emphasizes the broader significance of rare genetic diseases as innovation engines. These disorders, often characterized by relatively simple genetic etiologies, supply well-defined molecular targets that serve as ideal testing grounds for cutting-edge technologies. The lessons learned from these simplified systems are poised to catalyze breakthroughs in treating more complex, widespread conditions such as cancer, metabolic syndromes, and other multifactorial diseases—truly illustrating the ripple effect of targeted scientific inquiry.

A vital component propelling DIMERCIRCUITS forward is its integration of artificial intelligence during the design phase. Computational simulations guide the construction and optimization of genetic regulatory networks, forecasting circuit behavior before entering experimental validation. This synergy between in silico modeling and wet-lab experimentation accelerates discovery timelines and enhances the precision of the engineered circuits, allowing for iterative improvements and smarter therapeutic designs.

The project harnesses decades of systems biology insights, applying network theory to both elucidate disease pathways and engineer solutions—a hallmark of translational systems biology. By viewing cellular function as interconnected molecular circuits, di Bernardo’s team manipulates the underlying gene regulatory architecture rather than merely targeting symptomatic pathways, thus offering a fundamentally different approach to disease treatment.

Moreover, TIGEM’s unique research ecosystem fosters multidisciplinary collaboration, where computational biology, cell engineering, high-throughput screening, and clinical research converge seamlessly. This integration is vital for the success of such a technologically sophisticated endeavor. With a remarkable track record of 18 ERC grants awarded so far, TIGEM solidifies its role as a European powerhouse driving biomedical innovation and promoting the translation of foundational science into tangible medical applications.

The implications of DIMERCIRCUITS extend far beyond Friedreich’s ataxia. Once perfected, its modular genetic circuits can be tailored to regulate genes involved in a plethora of diseases characterized by dosage sensitivity. The potential to reversibly and dynamically tune gene expression paves the way for innovative therapies that could transform the management of disorders previously deemed intractable due to complexities in gene regulation and safety profiles.

Looking ahead, the fusion of artificial intelligence and synthetic biology represented in DIMERCIRCUITS signals a new era for personalized medicine—one where therapeutic interventions are custom-designed at the genetic and cellular level with unmatched specificity and control. Such advancements not only underscore the power of interdisciplinary science but also embody a hopeful vision for patients afflicted with genetic diseases worldwide.

By pushing the boundaries of what is scientifically achievable, di Bernardo and his team exemplify how visionary funding, cutting-edge technology, and a strategic focus on rare diseases can generate ripple effects that redefine the future of medicine. The emerging field of programmable genetic circuits is set to become a cornerstone of next-generation therapies, offering precision, adaptability, and safety that traditional approaches have so far struggled to achieve.

This story of innovation is also a testament to the importance of collaborative scientific ecosystems where experimental and computational disciplines intermingle, enabling breakthroughs that may soon transition from research laboratories into clinical reality. As DIMERCIRCUITS progresses, it holds the promise to shift the gene therapy landscape towards smarter, safer, and more effective treatments, transforming lives affected by genetic disorders on a global scale.

Subject of Research: Development of programmable DNA-based circuits for precise gene expression control in human cells, with application to treating rare genetic disorders such as Friedreich’s ataxia.

Article Title: Harnessing Intelligent Genetic Circuits: The Next Frontier in Gene Therapy at TIGEM

News Publication Date: Not specified

Web References:
– https://www.tigem.it/research/research-faculty/di-bernardo
– https://www.tigem.it/
– https://research.hsr.it/en/divisions/neuroscience/stem-cells-and-neurogenesis/vania-broccoli.html

Image Credits: Telethon Institute of Genetics and Medicine (TIGEM)

Keywords: gene therapy, synthetic biology, artificial intelligence, biomedical engineering, DNA circuits, programmable gene expression, engineered transcription factors, Friedreich’s ataxia, brain organoids, translational systems biology, personalized medicine, TIGEM, DIMERCIRCUITS